Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-centre Study of Lapatinib in Combinationwith Chemotherapy in Patients With ErbB2 Overexpressing Breastcancer After Trastuzumab Failure in the Neoadjuvant or Adjuvantsetting.

NCT00479856 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00479856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00479856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-centre Study of Lapatinib in Combinationwith Chemotherapy in Patients With ErbB2 Overexpressing Breastcancer After Trastuzumab Failure in the Neoadjuvant or Adjuvantsetting.
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2007
Completion date
March 31, 2010
Enrollment
9 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, breast, relapsed breast cancer